



Samrat Pharmachem Limited

Manufacturers & Exporters of Pharmaceutical Chemicals

Regd. Office & Factory

Plot No. A2/3444-3445, GIDC,
Phase 4, Ankleshwar - 393002,
Gujarat, India.
Phone: +91-7045456789 / 7046456789
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLCO17820

Corporate Office

701/702, Business Square,
M. A. Road, Andheri (West),
Mumbai - 400 058, India.
Phone: +91-7507534567 / 8760345678
E: contact@samratpharmachem.in

June 3, 2025

To,
Department of Corporate Services,
BSE Limited
P J Towers,
Dalal Street,
Mumbai - 400 001.

Scrip: 530125

Dear Sir,

Sub: Credit Rating – ISIN: INE103E01016

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we wish to inform you Crisil Limited has upgraded its rating on the bank facilities to 'Crisil BBB-/Stable/Crisil A3' from 'Crisil BB+/Stable/Crisil A4+'.

Annexure - Details of Instrument(s)

Name Of Instrument	Date Of Allotment	Coupon Rate (%)	Maturity Date	Issue Size (Rs.Crore)	Complexity Levels	Rating Outstanding with Outlook
Cash Credit	NA	NA	NA	28.00	NA	Crisil BBB-/Stable
Foreign Exchange Forward	NA	NA	NA	2.00	NA	Crisil A3

The above information will also be available on the website of the Company at www.samratpharmachem.com

Kindly take the same on record and acknowledge.

Thanking you.

Yours faithfully,
For Samrat Pharmachem Limited

Nishant Kankaria
Company Secretary & Compliance Officer

Rating Rationale

May 26, 2025 | Mumbai

Samrat Pharmachem Limited

Ratings upgraded to 'Crisil BBB-/Stable/Crisil A3'

Rating Action

Total Bank Loan Facilities Rated	Rs.30 Crore
Long Term Rating	Crisil BBB-/Stable (Upgraded from 'Crisil BB+/Stable')
Short Term Rating	Crisil A3 (Upgraded from 'Crisil A4+')

Note: None of the Directors on Crisil Ratings Limited's Board are members of rating committee and thus do not participate in discussion or assignment of any ratings.

The Board of Directors also does not discuss any ratings at its meetings.

1 crore = 10 million

Refer to Annexure for Details of Instruments & Bank Facilities

Detailed Rationale

Crisil Ratings has upgraded its ratings on the bank facilities of Samrat Pharmachem Ltd (SPL) to '**Crisil BBB-/Stable/Crisil A3**' from 'Crisil BB+/Stable/Crisil A4+'.

The rating upgrade reflects the improvement in the company's business risk profile, supported by increase in revenue and operating margin in 9M FY2025 to Rs 214 crore and 4.7%, respectively. The capital structure was strong owing to low reliance on external debt, yielding gearing and total outside liabilities to adjusted networth ratio of 0.13 time and 0.91 time, respectively, with networth of Rs 64.99 crore as on March 31, 2024.

The ratings continue to reflect the established market position of SPL and extensive experience of the promoters in the iodine manufacturing industry and the company's healthy financial risk profile. These strengths are partially offset by susceptibility to raw material prices and foreign exchange (forex) rates and large working capital requirement.

Analytical Approach

Crisil Ratings has evaluated the standalone business and financial risk profiles of SPL.

Key Rating Drivers & Detailed Description

Strengths:

- **Established market position and extensive experience of the promoters:** The company has been manufacturing iodine derivatives for three decades. This has helped the promoters develop understanding of the market dynamics and establish healthy relationships with suppliers and customers. Over the years, SPL has increased its product range to various industrial segments such as pharmaceuticals, fast-moving consumer goods (FMCG), animal feed and agrochemicals. This has led to the improvement in revenue profile with average growth of 28% over the last five fiscals to Rs 281.64 crore in fiscal 2024 from Rs 92.7 crore in fiscal 2018. The company achieved revenue of Rs 214.6 crore in the nine months of fiscal 2025
- **Healthy financial risk profile:** The capital structure was strong owing to low reliance on external debt, yielding gearing and total outside liabilities to adjusted networth ratio of 0.13 time and 0.91 time, respectively, with networth of Rs 64.99 crore as on March 31, 2024. Debt protection metrics were adequate as reflected in interest coverage and net cash accrual to total debt ratios of 5.51 times and 0.30 time, respectively, in fiscal 2024. The financial risk profile will remain comfortable over the medium term supported by steady accretion to reserve and nil debt-funded capital expenditure (capex) planned.

Weaknesses:

- **Susceptibility to raw material prices and forex rates:** Clientele comprises large, established players leading to limited pricing power for SPL. Furthermore, limited complexity of operations constrains profitability. The price of the major raw material, iodine, is volatile and depends on global demand and supply. The operating margin remained at 3-7% over the three fiscals through 2023 and stood at 0.57% in the nine months of fiscal 2024. The operating margin will remain monitorable. Although operating margin seen improvement in 9M FY2025 where company reported operating margin of ~ 6.5% for Q3 FY2025.

Since the majority of procurement comes from the international market, sharp fluctuation in forex rates affects procurement cost and accrual. This exposes the operating margin to fluctuation in forex rates.

- **Modest working capital cycle:** Gross current assets (GCAs) were at 117-136 days over the three fiscals through 2024. Modest working capital management is reflected in GCAs of 136 days with inventory and receivables of 27 and 90 days, respectively, as on March 31, 2024. It is required to extend the long credit period in line with the industry standards as

the customers are small and medium-sized players who require credit. Furthermore, to meet its business requirement, the company holds large work in progress inventory.

Liquidity: Adequate

Bank limit utilisation was low at 18% on average for the 12 months ended December 31, 2024. Annual cash accrual is expected over Rs 10 crore against nil term debt obligation over the medium term and will cushion liquidity. The current ratio was healthy at 1.78 times as on March 31, 2024. Low gearing and moderate network support financial flexibility, which will help to withstand adverse conditions or downturn in the business.

Outlook: Stable

Crisil Ratings believes SPL will continue to benefit from the extensive experience of its promoters and established relationships with clients.

Rating Sensitivity Factors

Upward factors:

- Sustained increase in revenue by 15-20% with operating margin reaching 7-8% on sustained basis
- Improvement in the working capital cycle.

Downward factors:

- Decline in net cash accrual below Rs 5 crore on account of fall in revenue or operating profit
- Large, debt-funded capex, weakening the capital structure
- Further stretch in the working capital cycle, weakening liquidity and financial risk profile

About the Company

SPL was incorporated in June 1992 at Ankleshwar in Gujarat. The company is promoted by Lalit Mehta and Rajesh Mehta. It manufactures iodine compounds used in pharmaceuticals, FMCG, animal feed, chemicals and agrochemicals. The company became a public limited company in 1995 and is listed on the Bombay Stock Exchange.

Key Financial Indicators

As on/for the period ended March 31	Unit	2024	2023
Operating income	Rs.Crore	281.64	310.75
Reported profit after tax (PAT)	Rs.Crore	2.24	16.42
PAT margin	%	0.77	5.35
Adjusted debt/adjusted networkth	Times	0.13	0.30
Interest coverage	Times	3.70	19.63

Any other information: Not applicable

Note on complexity levels of the rated instrument:

Crisil Ratings' complexity levels are assigned to various types of financial instruments and are included (where applicable) in the 'Annexure - Details of Instrument' in this Rating Rationale.

Crisil Ratings will disclose complexity level for all securities - including those that are yet to be placed - based on available information. The complexity level for instruments may be updated, where required, in the rating rationale published subsequent to the issuance of the instrument when details on such features are available.

For more details on the Crisil Ratings' complexity levels please visit www.crisilratings.com. Users may also call the Customer Service Helpdesk with queries on specific instruments.

Annexure - Details of Instrument(s)

ISIN	Name Of Instrument	Date Of Allotment	Coupon Rate (%)	Maturity Date	Issue Size (Rs.Crore)	Complexity Levels	Rating Outstanding with Outlook
NA	Cash Credit	NA	NA	NA	28.00	NA	Crisil BBB-/Stable
NA	Foreign Exchange Forward	NA	NA	NA	2.00	NA	Crisil A3

Annexure - Rating History for last 3 Years

		Current		2025 (History)		2024		2023		2022		Start of 2022
Instrument	Type	Outstanding Amount	Rating	Date	Rating	Date	Rating	Date	Rating	Date	Rating	Rating
Fund Based Facilities	ST/LT	30.0	Crisil A3 / Crisil BBB-/Stable		--	27-02-24	Crisil A4+ / Crisil BB+/Stable		--	30-12-22	Crisil A4+ / Crisil BB+ /Stable(Issuer Not Cooperating)*	Crisil BB+/Stable
			--		--	11-01-24	Withdrawn (Issuer Not Cooperating)*		--	26-04-22	Crisil A3 / Crisil BBB-/Stable	--
			--		--		--		--	11-03-22	Withdrawn (Issuer Not	--

			--	--	--	--	--	31-01-22	Cooperating)*	--
			--	--	--	--	--	31-01-22	Crisil BB+ /Stable(Issuer Not Cooperating)*	--
Non-Fund Based Facilities	ST		--	--	11-01-24	Withdrawn (Issuer Not Cooperating)*	--	30-12-22	Crisil A4+ (Issuer Not Cooperating)*	--
			--	--		--	--	26-04-22	Crisil A3	--

All amounts are in Rs.Cr.

* - Issuer did not cooperate; based on best-available information

Annexure - Details of Bank Lenders & Facilities

Facility	Amount (Rs.Crore)	Name of Lender	Rating
Cash Credit	28	ICICI Bank Limited	Crisil BBB-/Stable
Foreign Exchange Forward	2	ICICI Bank Limited	Crisil A3

Criteria Details

Links to related criteria
Basics of Ratings (including default recognition, assessing information adequacy)

Media Relations	Analytical Contacts	Customer Service Helpdesk
Ramkumar Uppara Media Relations Crisil Limited M: +91 98201 77907 B: +91 22 6137 3000 ramkumar.uppara@crisil.com	Nitin Kansal Director Crisil Ratings Limited B:+91 124 672 2000 nitin.kansal@crisil.com	Timings: 10.00 am to 7.00 pm Toll free Number:1800 267 3850 For a copy of Rationales / Rating Reports: CRISILratingdesk@crisil.com
Kartik Behl Media Relations Crisil Limited M: +91 90043 33899 B: +91 22 6137 3000 kartik.behl@crisil.com	Nilesh Agarwal Associate Director Crisil Ratings Limited B:+91 79 4024 4500 nilesh.agarwal1@crisil.com	For Analytical queries: ratingsinvestordesk@crisil.com
Divya Pillai Media Relations Crisil Limited M: +91 86573 53090 B: +91 22 6137 3000 divya.pillai1@ext-crisil.com	Dishantsinh Parmar Manager Crisil Ratings Limited B:+91 79 4024 4500 Dishantsinh.Parmar@crisil.com	